dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Im, Seock-Ah |
dc.contributor.author | Cardoso, Fatima |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Musolino, Antonio |
dc.contributor.author | Saura Manich, Cristina |
dc.contributor.author | Rugo, Hope |
dc.contributor.author | Curigliano, Giuseppe |
dc.date.accessioned | 2022-06-13T10:06:57Z |
dc.date.available | 2022-06-13T10:06:57Z |
dc.date.issued | 2021-04 |
dc.identifier.citation | Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. JAMA Oncol. 2021 Apr;7(4):573-84. |
dc.identifier.issn | 2374-2445 |
dc.identifier.uri | https://hdl.handle.net/11351/7665 |
dc.description | Càncer de mama avançat; Eficàcia; Margetuximab |
dc.description.sponsorship | This study was supported by MacroGenics, Inc. |
dc.language.iso | eng |
dc.publisher | American Medical Association |
dc.relation.ispartofseries | JAMA Oncology;7(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Treatment Outcome |
dc.title | Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1001/jamaoncol.2020.7932 |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1001/jamaoncol.2020.7932 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Rugo HS] University of California San Francisco Helen Diller Family Comprehensive Cancer Center. [Im SA] Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. [Cardoso F] Champalimaud Clinical Center/Champalimaud Foundation, Breast Unit, Lisbon, Portugal. [Cortés J] IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Curigliano G] European Institute of Oncology, IRCCS, Division of Early Drug Development, University of Milano, Milan, Italy. [Musolino A] Department of Medicine and Surgery, University of Parma, Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy. [Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 33480963 |
dc.identifier.wos | 000609546400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |